Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
Overall risk of myopericarditis low after COVID-19 vaccine
Apr 12, 2022
The overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Moderna asks FDA to approve second booster for all adults
Mar 18, 2022
The Moderna request covers all adults to give federal health officials the freedom to determine who should get a second booster.
Risk for blood clots after COVID-19 vaccination explored
Mar 11, 2022
Two studies show an increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1-S.
Vaccination ups infection-acquired immunity against SARS-CoV-2
Mar 01, 2022
Two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were linked to high short-term protection against infection, which wanes after six months.
COVID-19 vaccination tied to decline in distress in U.S. adults
Feb 24, 2022
Decreases in distress and perceived risks for infection, hospitalization and death were reported by those receiving at least one dose of the vaccine.
Low risk seen for second allergic reaction to mRNA COVID-19 vaccine
Feb 22, 2022
Of 1,366 patients with an immediate allergic reaction to the first dose, six developed a severe immediate allergic reaction after the second dose.
Homologous, heterologous COVID-19 boosters are immunogenic
Feb 07, 2022
Antibody neutralizing titers against SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations.